Oncology Institute (TOIIW) Equity Average (2020 - 2026)

Oncology Institute has reported Equity Average for 7 years, with the latest figure at -$16.0 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 469.66% year-over-year to -$16.0 million; the trailing twelve-month figure through Mar 2026 stood at -$16.0 million (down 469.66% YoY), and the FY2025 full-year result was -$6.1 million, down 120.01% from the prior year.
• Equity Average for Q1 2026 stood at -$16.0 million, down from -$14.0 million in the prior quarter.
• The five-year high for Equity Average was $128.0 million in Q2 2022, with the low at -$16.0 million in Q1 2026.
• Historically, Equity Average has averaged $54.2 million across 5 years, with a median of $49.2 million in 2024.
• Annual changes were most pronounced in 2022 — Equity Average jumped 213.84% — and 2026, when it plunged 469.66%.
• Oncology Institute's Equity Average stood at $125.6 million in 2022, then plunged by 48.68% to $64.4 million in 2023, then plunged by 85.2% to $9.5 million in 2024, then sank by 246.79% to -$14.0 million in 2025, then decreased by 14.33% to -$16.0 million in 2026.
• The last three Equity Average figures came in at -$16.0 million (Q1 2026), -$14.0 million (Q4 2025), and -$10.6 million (Q3 2025), per Business Quant data.